A case of miliary tuberculosis after prophylactic therapy for latent tuberculosis
Abstract
A 74-year-old man was referred to our hospital with persistent fever and fatigue. He had been receiving Golimumab for rheumatoid arthritis for 15 months. At the time of GLM initiation, latent tuberculosis (TB) was suspected, and Isoniazid was prophylactically administered for 8 months. Fifteen months after Golimumab initiation, he developed the symptoms. Reactivation of latent TB was suspected, however, chest and abdominal CT revealed no abnormal findings, and acid-fast bacillus smear and PCR tests from sputum, urine, blood, and gastric juice samples were negative for TB. Given that blood tests showed elevated hepatobiliary enzymes, miliary TB was suspected, and liver biopsy was performed, revealing caseous necrosis. Therefore, he was diagnosed with reactivation of latent TB caused by INH-resistant Mycobacterium tuberculosis. Following the treatment of rifampicin, ethambutol, levofloxacin, and streptomycin, the fever quickly resolved, and hepatobiliary enzyme levels were normalized. Culture of the liver biopsy tissue for acid-fast bacilli yielded INH-sensitive Mycobacterium tuberculosis. Although very rare, our case underscores that careful observation for reactivation of latent TB is important for patients receiving TNFα inhibitors even after appropriate prophylactic treatment for latent TB. Liver biopsy should be considered, when elevated liver enzymes are observed in suspected cases of miliary TB.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.